Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer

Abstract The prognostic value of EGF-R, IGF-1-R and SS-R, and of cytosolic estrogen-regulated pS2 protein, was studied in patients (pts) with primary breast and advanced ovarian cancer. Ovarian cancer tissues were negative for pS2 (by immunoradiometric assay) IGF-1-R and EGF-R contents (by ligand binding assay, LBA) were of no or moderate prognostic value for breast cancer pts ( n = 214). For advanced ovarian cancer pts, EGF-R content determined by LBA ( n = 55) showed no prognostic value, whereas EGF-R status ( n = 55) determined by immunohistochemistry (MoAb 2E9) signiificantly correlated with progression of disease ( P n = 135; P n = 197; P